(NASDAQ: FHTX) Foghorn Therapeutics's forecast annual revenue growth rate of 16.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Foghorn Therapeutics's revenue in 2025 is $24,518,000.On average, 10 Wall Street analysts forecast FHTX's revenue for 2025 to be $1,885,250,321, with the lowest FHTX revenue forecast at $1,479,721,028, and the highest FHTX revenue forecast at $2,770,730,405. On average, 10 Wall Street analysts forecast FHTX's revenue for 2026 to be $1,852,507,125, with the lowest FHTX revenue forecast at $0, and the highest FHTX revenue forecast at $2,968,942,673.
In 2027, FHTX is forecast to generate $2,270,194,946 in revenue, with the lowest revenue forecast at $1,108,405,264 and the highest revenue forecast at $2,968,942,673.